Departing FDA chief will fight high drug prices in new post

After Scott Gottlieb, MD, steps down as commissioner of the FDA April 5, he will head back to the American Enterprise Institute to tackle the rising cost of prescription drugs, according to The Washington Post.

Advertisement

The 46-year-old physician, millionaire venture capitalist and cancer survivor plans to spend about a half-dozen days a month as a resident fellow at the conservative think tank. Before becoming FDA commissioner, Dr. Gottlieb wrote op-eds for the institute.

He announced in March he was leaving his position at the FDA to spend more time with his family. He had been commuting to Washington, D.C., from Connecticut weekly since his May 2017 appointment.

Beyond his work with the institute, Dr. Gottlieb plans to explore other opportunities, but “I don’t know what they are right now,” he told The Post.

More articles on pharmacy:
7 drugs projected to become blockbusters by 2023
3 insulin manufacturers to testify at House panel April 10
Cigna-Express Scripts cap out-of-pocket 30-day insulin costs at $25

At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.

Register to Attend Webinar

The Performance Gap Your Pharmacy Training Metrics Can’t See

Monday, August 10
12:00 PM - 1:00 PM CDT

Presenters: Michael Alexander, AudirieDr. Tina Moen, PharmD, TRC Healthcare

Advertisement

Next Up in Pharmacy

Advertisement

Comments are closed.